🚀 New Blog Alert! 🚀 Check out our latest RARE Blog interview from Laura Hulley with guest, Daniela Malik, a dynamic marketing director who transitioned from the pharmaceutical industry to the rare disease space! In this episode, Daniela shares her journey from working in cardiology and neurology across Europe to spearheading impactful strategies at Jazz Pharmaceuticals🌍 Discover her insights on: - Navigating career shifts within the life sciences sector - The importance of patient-centric approaches in rare diseases - Future aspirations to innovate and improve patient outcomes Don't miss out on this inspiring conversation... Read the blog and watch the full interview now! 👉 https://lnkd.in/eBi5YEYZ #RareDisease #RareDiseases #LifeSciences
SciPro’s Post
More Relevant Posts
-
Resident Physician at The Valley Health System | Doctor of Medicine | Former Harvard Scientist | Aspiring Cardiologist with a Passion for Cardiovascular Research and Innovation
I am excited to share that my novel research has been accepted for an oral presentation at the Cardiology World Conference 2024! This study opens new avenues for improving the quality of care in cardiology, with the potential to reduce morbidity and mortality over time. It also highlights the vital role economics and pharmaceutical companies can play in enhancing patient care and supporting decision-making in the field. I look forward to sharing the results as soon as the publication is out. Stay tuned! #cardiology #research
To view or add a comment, sign in
-
🧠 Alzheimer’s Drugs Market Poised for Rapid Growth 💊 The Alzheimer’s drugs market is on track to witness a robust CAGR of approximately 20% from 2024 to 2029. For more insights https://lnkd.in/dg89JP-4 🌍 This surge is fueled by a combination of factors, including the rising incidence of Alzheimer’s disease, an aging global population, and breakthrough innovations in drug discovery and development. With increased awareness, improved diagnosis, and significant investments in R&D, the focus is shifting towards novel therapies that target the root causes of Alzheimer’s, offering hope for more effective treatments. Key players driving this market transformation include industry giants such as Eli Lilly and Company, Johnson & Johnson, Sanofi, Novartis, Biogen, Eisai US, AbbVie, and several others. Their commitment to innovation is set to redefine the landscape of Alzheimer’s treatment in the coming years. #Alzheimers #Pharmaceuticals #DrugDevelopment #HealthcareInnovation #Biotech #HealthcareTrends #MedicalResearch #PharmaIndustry #DrugDiscovery #AgingPopulation #AlzheimersResearch #Innovation #LifeSciences #HealthTech #FutureOfHealthcare #AlzheimersDrugs #Neuropharma #Neurology #CNSDrugs #AlzheimersTreatment #NeurodegenerativeDiseases #BrainHealth #Neurotherapeutics #MemoryCare #CognitiveHealth #DementiaResearch #CNSResearch #PharmaInnovation #NeuroScience #CognitiveDisorders
To view or add a comment, sign in
-
Recently we shared a fresh case study with you in the field of lower back pain treatment. We’d like to point out that this was not our only experience in the area of neurology therapy. Some time ago we partnered with Dr Reddy’s Laboratories, a leading Indian pharmaceutical manufacturer, to conduct a multicenter, prospective, double-blind, randomized, parallel-group comparative study. Despite pandemic-related challenges, OCT Clinical achieved an impressive enrollment milestone two weeks ahead of schedule in a multicenter, double-blind study. Curious about the key milestones of this collaboration? Watch the video to find out more about our achievements! #neurologyresearch #clinicaltrials #octclinical #expertise
To view or add a comment, sign in
-
📢 Exciting Research Update from Icahn School of Medicine at Mount Sinai! 📢 Dr. Mirna Chehade, M.D., M.P.H., and colleagues conducted a study on children aged 1-11 with active eosinophilic esophagitis (EoE) who didn't respond to proton-pump inhibitors. The study, funded by Sanofi and Regeneron Pharmaceuticals, explored the efficacy of dupilumab. Patients were randomly assigned to receive either a higher- or lower-exposure subcutaneous dupilumab regimen or placebo over 16 weeks. The findings were promising: 🔹 68% of patients in the higher-exposure group achieved histologic remission. 🔹 58% in the lower-exposure group achieved histologic remission. 🔹 Only 3% in the placebo group achieved histologic remission. Significant improvements in histologic, endoscopic, and transcriptomic measures were noted with the higher-exposure dupilumab regimen compared to placebo. The benefits remained consistent over 52 weeks. "The higher-exposure regimen showed significant benefits as compared with placebo with respect to seven of the eight secondary endpoints," the authors wrote. For more detailed findings, check out the study abstract and editorial (subscription may be required). #EosinophilicEsophagitis #Dupilumab #PediatricResearch #IcahnSchoolOfMedicine #MountSinai #ClinicalResearch #Sanofi #RegeneronPharmaceuticals
To view or add a comment, sign in
-
🌟 Exciting News in Eye Disorder Research! Aviceda Therapeutics hits a huge milestone, as dosing begins for the second part of their Phase 2/3 SIGLEC Clinical Trial for Geographic Atrophy (GA)! Their therapy AVD-104 is a sialic acid-coated glycoimmune therapeutic, which binds activated macrophages and causes regulatory changes in cellular/ humoral innate immunity. The primary endpoint for part two is the difference in GA area growth rate, with additional measures assessing visual function and anatomy. 🚀 The Chief Medical Officer, Dr. David Callanan, emphasized the positive safety profile and BCVA improvements already observed in part 1. 👩⚕️ Aviceda Therapeutics' CEO Dr. Mohamed Genead envisions a paradigm shift in GA treatment with AVD-104's dual-mechanism approach. #EyeDisorderResearch #ClinicalTrials #AvicedaTherapeutics #AMD #InnovationInHealthcare #ElixirAssociates #clinical #pharmaceuticals #Geographicatrophy #innateimmunity #science #ophthalmology
To view or add a comment, sign in
-
𝐉𝐨𝐢𝐧 𝐨𝐮𝐫 𝐥𝐢𝐯𝐞 𝐰𝐞𝐛𝐢𝐧𝐚𝐫 - The use of generics, biosimilars and NBCDs for Multiple Sclerosis ⤵︎ Because MS usually has an onset in early adulthood and is a progressive disease, the economic burden is substantial, and disease-modifying treatments (DMTs) constitute a large proportion of healthcare costs. The use of generic versions (of synthetic drugs), biosimilars (for biologics) or follow-on versions of non-biologic complex drugs (NBCDs) can reduce the overall cost of MS care and improve patient access. In Europe, there are robust regulatory processes and effective oversight for generic, biosimilar and follow-on NBCDs of DMTs so that these agents can be considered interchangeable with the originator product. Physicians caring for patients with MS need to familiarise themselves with the evidence so that they can have informed conversations with their patients about the potential use of these agents. Register now to gain insights from experts and ultimately optimize MS treatment strategies and improve patient outcomes: https://lnkd.in/eNNtH9bZ #paradigmsfoundation #multiplesclerosis #patiencare #msresearch #MS #livewebinar #neurologist #neurology
To view or add a comment, sign in
-
AlzeCure Pharma @ JP Morgan - AlzeCure look forward to attend JP Morgan in San Francisco, presenting the company, and our Alzheimer’s and pain projects* to pharma companies and investors, and other stake holders We’ll be present from Sunday January 7 to Thursday, January 11 Please reach out to book meetings and to catch up: - info@alzecurepharma.com or directly to CEO Martin Jönsson martin.jonsson@alzecurepharma.com Safe Travel to everybody going to JP Morgan *) PROJECTS - Alzstatin – Gamma-Secretase Modulator to prevent or delay Alzheimer’s disease - NeuroRestore - Trk-PAM to improve learning and memory capabilities, and to prevent or delay Alzheimer’s disease - ACD440 – TRPV1 antagonist against peripheral neuropathic pain, with recent positive ph 2 data - TrkA-NAM – Down regulating NGF signaling, against osteoarthritis More on our projects at: https://lnkd.in/enfcx4G #alzecure #neurorestore #acd856 #Alzstatin #gammasecretasmodulator #alzheimer #dementia #neuroscience #alzheimerfonden #nordnet #avanza #erikpenserbank #redeye #aktiespararna #swedbank #analysguiden #finwire #placera #acd440 #trpv1abtagonist #trkanam
To view or add a comment, sign in
-
Research from We Work For Health and Vital Transformation shows that expansion of government-mandated drug pricing policies would have the most negative impacts on disease states with the greatest unmet need: oncology, neurology, infectious disease, and more. See the data: https://lnkd.in/gfDHw6uu
NEW STUDY: Proposed Government-Mandated Drug Pricing Policies Amount to 235+ Fewer FDA Approvals and Up To 1.1M Lost Jobs Over the Next 10 Years.
weworkforhealth.org
To view or add a comment, sign in
-
"We have successfully continued the development of HER-096 by submitting a phase 1b clinical trial application to regulatory authorities. In the trial, HER-096 will be administered for the first time to Parkinson's patients. The study provides significant new information about repeated subcutaneous administrations of HER-096 and will be essential for planning of future phase 2 studies. We expect to receive the phase 1b regulatory approval and start the study in the second half of 2024. Phase 1b trial funding has been secured from the two leading Parkinson's patient organisations: the Michael J Fox Foundation and Parkinson UK through their Virtual Biotech program. We negotiated the agreement during the first half of 2024 and signed it right after the review period on July 1, 2024. This is a significant achievement, as these highly respected organizations consider that HER-096 is one of the most promising new drug candidates for treatment of Parkinson's disease. This external validation is also very significant for the partnering discussions," said Antti Vuolanto, CEO of Herantis Pharma Plc. Read more: https://lnkd.in/dximgTTA #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology
To view or add a comment, sign in
-
🔵 Drug Discovery & Development | One Step through to Drug Product Development | Tech Transfer | Academic Research | Company Creation | Biotech
Simplify your #drugdevelopment challenges with the help of our experts who will guide you through the changing regulatory terrain with personalised, flexible, and responsive support. https://okt.to/7jwkqF #biotech #therapeutics #drugdiscovery #oncology #immunology #neuroscience #antibody #ophthalmology #cardiovascular #respiratory #inflammation #pharmaceuticals #chemistry #biology #CharlesRiver #Lifesciences #startups
Charles River Scientific Advisory Services
criver.com
To view or add a comment, sign in
91,031 followers